Citation Impact
Citing Papers
BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial
2013
Pathophysiology of Migraine: A Disorder of Sensory Processing
2017 Standout
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure
2017
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies
2018 StandoutNobel
Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease
2014
Amyloid‐ß‐directed immunotherapy for Alzheimer's disease
2014
Multi-input chemical control of protein dimerization for programming graded cellular responses
2019 StandoutNobel
Biotransformation of Two β-Secretase Inhibitors Including Ring Opening and Contraction of a Pyrimidine Ring
2013
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study
2015
Targeting Amyloidogenic Processing of APP in Alzheimer’s Disease
2020
Immune attack: the role of inflammation in Alzheimer disease
2015 Standout
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
2019 Standout
Modulation of γ- and β-Secretases as Early Prevention Against Alzheimer’s Disease
2017
Alzheimer's disease
2016 Standout
Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study
2016
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection
2016
Effects of Modafinil on the Sleep EEG Depend on Val158Met Genotype of COMT
2010
<p>Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics</p>
2019 Standout
Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4–5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial
2017
Hepatitis C Virus: 30 Years after Its Discovery
2019 StandoutNobel
Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens
2016
Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal
2016
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
2014
Randomized, Controlled Study of Telcagepant in Patients With Migraine and Coronary Artery Disease
2012
Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer’s disease
2016
Taming a beast: lessons from the domestication of hepatitis C virus
2019 StandoutNobel
CGRP and its receptors provide new insights into migraine pathophysiology
2010
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
2016
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
2020 Standout
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial
2015
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
2020 Standout
Alzheimer's disease
2017 Standout
Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study
2017
Magnesium in Man: Implications for Health and Disease
2014 Standout
The Organocatalytic Approach to Enantiopure 2H‐ and 3H‐Pyrroles: Inhibitors of the Hedgehog Signaling Pathway
2016 StandoutNobel
Protease inhibitor therapy for hepatitis C virus-infection
2018
Inflammation as a central mechanism in Alzheimer's disease
2018 Standout
Neuropathic Pain: From Mechanisms to Treatment
2020 Standout
About Sleep's Role in Memory
2013 Standout
Emerging Therapeutics for Alzheimer's Disease
2014
The role of calcitonin gene–related peptide in peripheral and central pain mechanisms including migraine
2017
Organokatalytische Synthese von enantiomerenreinen 2H‐ und 3H‐Pyrrolen: Inhibitoren des Hedgehog‐Signalwegs
2016 StandoutNobel
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Calcitonin Gene‐Related Peptide ( CGRP ) and Migraine Current Understanding and State of Development
2013
Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells
2019 StandoutNobel
Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP
2014
Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine
2011
Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection
2016 StandoutNobel
Calcitonin Gene-Related Peptide: Physiology and Pathophysiology
2014
Works of John Palcza being referenced
Blockade of Capsaicin-Induced Dermal Vasodilatation (CIDV) by MK-3207, a Calcitonin-Gene Related Peptide (CGRP) Receptor Antagonist for Acute Treatment of Migraine
2009
MK-0974, a novel oral CGRP antagonist, exhibits similar pharmacokinetics during and between migraine attacks
2007
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE: Table 1.
2015
A Randomized, Placebo-Controlled Study of the Effects of Telcagepant on Exercise Time in Patients With Stable Angina
2012
Inhibition of capsaicin‐induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK‐0974)
2009
The potent calcitonin gene‐related peptide receptor antagonist, telcagepant, does not affect nitroglycerin‐induced vasodilation in healthy men
2010
Effect of Telcagepant on Spontaneous Ischemia in Cardiovascular Patients in a Randomized Study
2011
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent
2015
Lack of hemodynamic interaction between CGRP-receptor antagonist telcagepant (MK-0974) and sumatriptan: Results from a randomized study in patients with migraine
2013
O001 : C-salvage: grazoprevir (GZR; MK-5172), elbasvir (EBR; MK-8742) and ribavirin (RBV) for chronic hcv-genotype 1 (GT1) infection after failure of direct-acting antiviral (DAA) therapy
2015
THE CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONIST TELCAGEPANT DOES NOT REDUCE EXERCISE TOLERANCE IN PATIENTS WITH EXERCISE INDUCED MYOCARDIAL ISCHEMIA
2010
The Novel BACE Inhibitor MK-8931 Dramatically Lowers CSF A Peptides in Healthy Subjects: Results from a Rising Single Dose Study (PL02.004)
2012
P4‐196: The novel BACE inhibitor MK‐8931 dramatically lowers cerebrospinal fluid Aβ peptides in healthy subjects following single‐ and multiple‐dose administration
2012
Effects of a single dose of modafinil on EEG during the MWT during acute sleep deprivation
2008